Immune Function Monitoring and Immunotherapy in Sepsis

Immune Function Monitoring and Immunotherapy in Sepsis: a Cross-sectional Survey in China

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04903405

Acronym

IMITS

Enrollment

5000

Registered

2021-05-26

Start date

2021-06-01

Completion date

2021-07-30

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Septic Shock

Brief summary

At present, the clinical studies of various anti-inflammatory drugs and immune-enhancing drugs show that immunotherapy will bring new hope for the treatment of sepsis. In order to further understand the current status of immunotherapy in China, this study aims to understand the current status and standardization of the use of sepsis immunosurveillance and immunotherapy in hospitals through a cross-sectional survey.

Interventions

OTHERNo intervention

No intervention is involved in this study

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with sepsis or septic shock according to Sepsis 3.0

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame
28-day mortality	28 days

Secondary

Measure	Time frame
Percentage of sepsis patients receiving immune function monitoring	28 days
Percentage of sepsis patients receiving immunotherapy	28 days

Contacts

Primary ContactJianfeng Wu

wujianf@mail.sysu.edu.cn020-87755766-8453

Backup ContactFei Pei

peif3@mail.sysu.edu.cn020-87755766-8453

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026